prikaz prve stranice dokumenta Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting
  Preuzmi
PDF 513.33 KB
Znanstveni rad - Izvorni znanstveni rad
Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting
Acta Neurobiol Exp, 72 (2012), 3; 264-271. urn:nbn:hr:184:933151
Malnar, Martina; Kosiček, Marko; Bene, Raphael; Petek Tarnik, Iva; Pavelin, Sanda; Babić, Ivana; Brajenović-Milić, Bojana; Hećimovic, Hrvoje; Titlić, Marina; Trkanjec, Zlatko; Demarin, Vida; Hećimović, Silva

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Malnar, M., Kosiček, M., Bene, R., Petek Tarnik, I., Pavelin, S., Babić, I. ... Hećimović, S. (2012). Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting. Acta Neurobiol Exp, 72. (3), 264-271. Preuzeto s https://urn.nsk.hr/urn:nbn:hr:184:933151

Malnar, Martina, et al. "Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting." Acta Neurobiol Exp, vol. 72, br. 3, 2012, str. 264-271. https://urn.nsk.hr/urn:nbn:hr:184:933151

Malnar, Martina, Marko Kosiček, Raphael Bene, Iva Petek Tarnik, Sanda Pavelin, Ivana Babić, Bojana Brajenović Milić, et al. "Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting." Acta Neurobiol Exp 72, br. 3 (2012): 264-271. https://urn.nsk.hr/urn:nbn:hr:184:933151

Malnar, M., et al. (2012) 'Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting', Acta Neurobiol Exp, 72(3), str. 264-271. Preuzeto s: https://urn.nsk.hr/urn:nbn:hr:184:933151 (Datum pristupa: 12.05.2024.)

Malnar M, Kosiček M, Bene R, Petek Tarnik I, Pavelin S, Babić I, i sur.. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting. Acta Neurobiol Exp [Internet]. 2012. [pristupljeno 12.05.2024.];72(3):264-271. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:933151

M. Malnar, et al., "Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting", Acta Neurobiol Exp, vol. 72, br. 3, str. 264-271, 2012. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:933151. [Citirano: 12.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:933151
Podaci o radu
Naslov (engleski)Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting
AutorMartina Malnar
AutorMarko Kosiček
AutorRaphael Bene
AutorIva Petek Tarnik
AutorSanda Pavelin
AutorIvana Babić
AutorBojana Brajenović-Milić
AutorHrvoje Hećimovic
AutorMarina Titlić
AutorZlatko Trkanjec
AutorVida Demarin
AutorSilva Hećimović
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za medicinsku biologiju i genetiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Low levels of amyloid-β42 (Aβ42) and high total-tau (t-tau) or phosphorylated-tau (p181-tau) levels in cerebrospinal fluid (CSF) were shown to be characteristic for Alzheimer’s disease (AD) patients and for mildly cognitively impaired (MCI) or non-demented individuals who will progress to AD. The goal of this study was to evaluate the benefit of CSF biomarker testing in a setting with no specialized dementia centers, in order to improve the accuracy of AD diagnosis and to identify individuals with incipient AD. Using ELISA assay we analyzed CSF Aβ42, t-tau and p181-tau levels among clinically diagnosed non-demented individuals, AD patients and individuals with uncertain dementia (n=36). CSF cut-off values of low Aβ42 (≤530 pg/mL) and high t-tau (≥350 pg/mL) or p181-tau (≥52 pg/mL) were used to identify individuals with AD/ MCI-CSF profile, regardless of clinical diagnosis. APOE genotyping was performed using PCR-RFLP method. In accord with previous studies we detected significantly decreased levels of CSF Aβ42 and increased tau and p181-tau levels in clinically diagnosed AD group vs. non-demented controls. CSF profiling identified individuals with a typical AD/MCI-CSF pattern in clinically referred non-demented group (9%) and among patients with uncertain dementia (41.7%). APOE ε4-allele was associated with the CSF biomarker changes typical for AD. This study shows that in a non-specialized setting CSF biomarker testing may be used as a screening tool for improving the accuracy of AD diagnosis and for predicting individuals with incipient Alzheimer’s disease who need to receive further clinical follow-up.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaActa Neurobiol Exp
Brojčani podacivol. 72, br. 3, str. 264-271
e-ISSN1689-0035
URN:NBNurn:nbn:hr:184:933151
Datum objave publikacije2012
URL dokumentahttp://www.ane.pl/pdf/7224.pdf
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2017-06-14 09:33:19